St. Jude Medical Inc. (STJ) Pops 3.25% for January 12

Equities Staff |

One of the S&P 500’s big winners for Tuesday January 12 was St. Jude Medical Inc. (STJ) as the company’s stock climbed 3.25% to $59.04 on volume of 2.46 million shares.

The stock opened at $57.65 and saw an intraday low of $57.64 and an intraday high of $59.17. All told, the day saw a per-share gain of $1.86. The stock’s average daily volume of 1.79 million and 282.66 million shares outstanding. St. Jude Medical Inc. now has a 50-day SMA is $61.82 and 200-day SMA is $67.94, and it has a 52-week high of $80.84 and a 52-week low of $56.30.

St Jude Medical Inc develops, manufactures and distributes cardiovascular medical devices for global cardiac rhythm management, cardiovascular, atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain.

Based out of St. Paul, MN, St. Jude Medical Inc. has 16,000 employees and, after today’s trading, reached a market cap of $16.69 billion. Its P/S ratio is n/a, P/B ratio is 4.18, and P/FCF ratio is 33.1.

For a complete fundamental analysis analysis of St. Jude Medical Inc., check out’s Stock Valuation Analysis report for STJ. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Initial State

Initial State is an Internet of Things (IoT) data analytics & data management platform company. We turn sensor and event data into information that matters by making it easy to…


D-Wave Systems is the first quantum computing company. Its mission is to integrate new discoveries in physics, engineering, manufacturing, and computer science into breakthrough approaches to computation to help solve…